The board of directors of Mabpharm Limited announced that Mr. Li Yunfeng (?Mr. Li?) will no longer holds the position of chief financial officer of the Company with effect from July 10, 2024. Mr. Li Yunfeng, aged 47, and was appointed as an executive Director since July 20, 2018. He is primarily responsible for overseeing the management of market development, investment and legal work of Group.

Mr. Li joined Group and served as a deputy general manager of Taizhou Pharmaceutical since March 2016, and was appointed as a director of Taizhou Pharmaceutical and Shengheng Biotechnology in August 2018 and November 2019, respectively. Mr. Li has over 20 years of experience in the biotechnology industry, which in the Directors' view, enables him to competently carry out responsibilities in Group. From January 2002 to June 2009, and from July 2010 to November 2012, Mr. Li was employed by Shanghai CP Guojian Pharmaceutical Co.

Ltd. as a deputy general manager. Mr. Li worked as a deputy general manager at Shanghai National Engineering Research Center of Antibody Medicine Co. Ltd. from July 2009 to June 2010 and a general manager of Shanghai Lansheng Guojian Pharmaceutical Co.

Ltd. from December 2012 to March 2016. Mr. Li served as a deputy general manager of Zhangjiang Biotechnology from March 2016 to July 2017. He also worked as a deputy general manager of Biomabs and MTJA respectively from March 2016 to August 2018.

Mr. Li obtained a bachelor degree in international economics from Nanjing Normal University in July 1998.